Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.
about
Inhibition of polymorphic human carbonyl reductase 1 (CBR1) by the cardioprotectant flavonoid 7-monohydroxyethyl rutoside (monoHER)Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative StressDexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in MiceAnthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release.Anthracycline cardiotoxicity: prevalence, pathogenesis and treatmentActivation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heartDoxorubicin pathways: pharmacodynamics and adverse effects.National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage aManaging chemotherapy-related cardiotoxicity in survivors of childhood cancers.Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.Protective Effects of Dexrazoxane against Doxorubicin-Induced Cardiotoxicity: A Metabolomic Study.Cytotoxic Effect of Thymus caramanicus Jalas on Human Oral Epidermoid Carcinoma KB Cells.The role of genetic variability in drug metabolism pathways in breast cancer prognosis.Molecular control of vertebrate iron homeostasis by iron regulatory proteinsA four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trialsThe regulatory mechanisms of myogenin expression in doxorubicin-treated rat cardiomyocytesGenetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation.Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failureCardiovascular disease in survivors of hematopoietic cell transplantation.The role of iron in anthracycline cardiotoxicity.TVP1022 protects neonatal rat ventricular myocytes against doxorubicin-induced functional derangements.Late Cardiotoxicity: Issues for Childhood Cancer Survivors.The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient.Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.Immunocytochemistry for drugs containing an aliphatic primary amino group in the molecule, anticancer antibiotic daunomycin as a model.Rutin Protects against Pirarubicin-Induced Cardiotoxicity through TGF-β1-p38 MAPK Signaling Pathway.Doxorubicin induces EGF receptor-dependent downregulation of gap junctional intercellular communication in rat liver epithelial cells.Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase IIβ activity and cardiac function in a chronic rabbit model.Effects of age on multidrug resistance protein expression and doxorubicin accumulation in cardiac and skeletal muscle.THE ROLE OF PROTEIN CHAPERONES IN THE SURVIVAL FROM ANTHRACYCLINE-INDUCED OXIDATIVE STRESS IN SACCHAROMYCES CEREVISIAE.Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.The Role of HSP40 Conserved Motifs in the Response to Cytotoxic Stress.
P2860
Q24336929-8C61102F-B656-4476-BEB0-80BE9FB459FDQ26780547-B2113B4A-663F-4427-9C41-47B6F378B8FDQ27345163-ADA769AC-129B-4803-9A8C-9CE08E7B887DQ33341069-917427B2-29B3-496A-BBAE-6EE0E6118957Q33913079-C4929645-BA42-4286-AAB8-FB7C508E6F81Q34639876-F28909DC-911C-41E8-A565-143235CAC0AAQ34808490-0DE01D77-E4AD-48BA-8C3F-B29B4E3683A2Q35048393-2C359108-74A1-4912-96F1-D0CFCB2C1204Q35549037-2208F88E-F74F-46C2-AA27-546332A75120Q35562745-197A5FCB-EAAA-4A7F-90A0-ADE2E8350067Q36184665-AF6B5DFE-B361-452D-8D58-179656B7B9CBQ36245459-18B8845F-0115-4F9E-A181-4F631F9237A7Q36310309-43875269-0FBF-4609-9CBE-08AE1E7328DCQ36497088-06106E58-5C7F-4EAB-A1EB-19AF621610BEQ36536936-A08DE15E-53E8-45A8-A0CE-2DF59616D75CQ36544667-73ED1DAF-1726-47B7-8CFD-A9DE946D61B6Q36545773-46EEF9ED-8A72-42F7-92C3-BEADF6B0A07BQ37227651-E46A60A1-65DB-4B2B-86F2-17B86114F1ACQ37351248-5A8ED1E5-597A-431A-90D4-80110E27CB29Q37373704-E6F7F109-7510-4D47-AFB2-A94F565B5F0EQ37624268-61ACFE28-9255-45CE-80A6-2C7C5F419FF2Q38195038-687A871C-6E57-4657-AFEC-E00B7E94478CQ38838153-80920E9B-E825-4F07-A450-2DB125EAA7D7Q38845457-629F5AAD-D9C7-4778-AA91-23FF4C69D292Q38966370-49FE7696-80B1-4AF0-B69A-6F6057CF2073Q39608341-7BC6DEAC-8962-41ED-B42A-7103A2CC67EBQ40439716-09DE61CC-0104-426B-837A-4058F1EED66AQ41825099-5AFC1F83-32ED-4E24-B5A4-2382E74CD468Q46447814-D4C806CB-70D8-4864-8905-661D23BD5BE7Q48042771-52DA457F-E8D3-4894-A175-4C81CDAB9A72Q51192184-BB476707-AFBF-4294-80F0-F9BB45484BC2Q52587039-1C2BD7B0-3502-418E-AABE-64565FACC891Q54976923-3301558E-45C3-4DC1-A2E4-0CCF5C0AFC74Q55024465-3766DE85-79D5-4758-8B72-7FE2315F1008
P2860
Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@ast
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@en
type
label
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@ast
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@en
prefLabel
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@ast
Doxorubicin cardiotoxicity and ...... nt and independent mechanisms.
@en
P50
P1476
Doxorubicin cardiotoxicity and ...... ent and independent mechanisms
@en
P2093
Emanuela Salvatorelli
Gianfranca Corna
P304
P356
10.1016/S0076-6879(04)78025-8
P407
P577
2004-01-01T00:00:00Z